Not recruiting
Acute myeloid leukaemia
Not recruitingStudy on Gemtuzumab Ozogamicin and Gilteritinib for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Registered drugNo placebo
Study on Gemtuzumab Ozogamicin and Gilteritinib for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Registered drugNo placebo
- Disease:Acute myeloid leukaemia
- Substances:GilteritinibGemtuzumab Ozogamicin
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Gilteritinib
